A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Apr 2017 New trial record